Methods and compact markers for labeling biological samples
By introducing folded bound nucleic acid backbone and staple chain into biological samples, a compact marker is solved, and the problem of poor penetration of existing markers is achieved, and reliable detection and labeling of rare target analytes is achieved.
Patent Information
- Application Number
- CN202410639116.3
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Priority Date
- 2023-05-23
- Filing Date
- 2024-05-22
- Publication Date
- 2024-11-26
AI Technical Summary
Existing markers have poor penetration in biological samples, making it difficult to effectively detect rare target analytes, especially due to their large size, which leads to insufficient penetration to biological samples.
By introducing small nucleic acid backbone and staple chain, folded and bound in the biological sample, forming a compact marker, ensuring that the marker is produced in the biological sample, thereby achieving effective target analyte marker.
Effective penetration in biological samples and the generation of compact markers with sufficient optical properties is achieved, ensuring reliable labeling and detection of target analytes, and improving the reliability of biological samples imaging.
Smart Images

Figure CN119020465A_ABST
Abstract
Description
Technical Field
[0001] The present invention relates to methods and compact labels for labeling a biological sample comprising at least a first target analyte. Background Art
[0002] Biological samples (such as tissue sections) are usually analyzed after labeling the target analyte in the sample with a marker that is specific for the target analyte. For example, such a marker can include a fluorophore that allows the biological sample to be imaged by a microscope in order to study the spatial distribution of the target analyte in the biological sample. In order to be able to reliably detect these target analytes, in particular to detect only rare target analytes, it is necessary to provide a marker with optical properties that allow these markers to be easily identified. For example, a marker with a fluorophore needs to have a sufficiently bright fluorescence emission in order to reliably and routinely identify these markers in the marker biological sample.
[0003] Typically, labels with suitable optical properties, such as labels with several fluorophores, have trade-offs, such as their large size, which results in poor or insufficient penetration of the label into the biological sample. Summary of the invention
[0004] An object of the present invention is to provide a label and method for labeling a biological sample, which effectively penetrates the biological sample and provides sufficient optical properties.
[0005] The above objects are achieved by the subject-matter of the independent claims. Advantageous embodiments are defined in the dependent claims and in the following description.
[0006] A method for labeling a biological sample is provided, the method comprising the following steps: providing at least one first target analyte to the biological sample; introducing at least one first nucleic acid backbone, at least one first label configured to attach to the first nucleic acid backbone, and at least one first affinity reagent specific to the first target analyte and configured to attach to the first nucleic acid backbone into the biological sample; and introducing a first plurality of staple chains into the biological sample, each staple chain configured to hybridize with a pair of folding binding sites of the first nucleic acid backbone so as to fold the first nucleic acid backbone in the biological sample and produce a compact optically detectable first label.
[0007] Introducing at least one first nucleic acid backbone, at least one first mark and at least one first affinity reagent and introducing the first multiple staple chains enable to produce compact first markers in biological samples rather than outside biological samples. Because the first nucleic acid backbone and staple chains are small respectively, and / or have a high degree of freedom in their movement and bending, they easily and effectively penetrate biological samples. For example, the length of the staple chain is preferably 15 to 60 nucleotides. On the contrary, compact markers are bulky and cannot effectively penetrate biological samples. Because compact markers are produced in situ, target analytes can still be effectively labeled by compact markers.
[0008] Preferably, the compact label is formed by a first nucleic acid backbone, a first label and a first affinity reagent. The first label and the first affinity reagent may include an oligomer having a unique sequence at least partially complementary to the corresponding sequence of the nucleic acid backbone, for attaching the first label and the first affinity reagent to a predetermined position on the nucleic acid backbone.
[0009] Preferably, step b) and step c) are performed subsequently. Thus, step b) and step c) are preferably not performed simultaneously, but step c) is performed after step b) or step b) is performed after step c). This enables particularly efficient generation of the marker in the biological sample after the at least one first nucleic acid backbone, the at least one first label, the at least one first affinity reagent and / or the first plurality of staple chains of step b) and / or step c) have penetrated the biological sample.
[0010] Preferably, step d) is performed between step b) and step c): waiting for a time in the range of 10 seconds to 120 minutes, preferably waiting for a time in the range of 5 minutes to 90 minutes, more preferably waiting for a time in the range of 10 minutes to 60 minutes. This makes it possible to ensure at least one first nucleic acid backbone, at least one first label, at least one first affinity reagent and / or the first plurality of staple chains of step b) and / or step c). In particular, the time can depend on the temperature of the biological sample, for example, waiting for a time of 5 minutes at 45°C to 60°C, and waiting for a time of 10 minutes to 60 minutes at 37°C. In some cases, for example, when the entire mouse embryo or a large piece of tissue is to be stained, the waiting time can be greatly extended to several days. In this case, the method described in the document can be combined with an organic solvent-based or water-based clearing method (e.g., Spalteholz clearing and related techniques, CLARITY, Scale, Cubic, DISCO, iDISCO and similar methods). This may further facilitate penetration of the biological sample by the at least one first nucleic acid backbone, the at least one first label, the at least one first affinity agent, and / or the first plurality of staple chains.
[0011] Preferably, in step d), an electrophoretic electric field is additionally applied to the biological sample. This may enable or facilitate particularly efficient introduction of at least one first nucleic acid backbone, at least one first label, at least one first affinity reagent and / or the first plurality of staple chains into the biological sample. The field may have a stable or alternating directionality.
[0012] Preferably, the first nucleic acid backbone, the first label and the first affinity reagent of step b) are introduced into the first region of the biological sample, and the first plurality of staple chains of step c) are introduced into the second region of the biological sample, wherein the first region and the second region are spatially separated from each other. In particular, in this case, at least one first nucleic acid backbone, at least one first label, at least one first affinity reagent and / or the first plurality of staple chains can be introduced into the biological sample at the same time. This makes it possible to introduce at least one first nucleic acid backbone, at least one first label, at least one first affinity reagent and / or the first plurality of staple chains into the biological sample particularly effectively. For example, in the case where the biological sample is a planar tissue section, at least one first nucleic acid backbone, at least one first label and at least one first affinity reagent can be introduced into the biological sample from one side of the plane of the tissue section, and the first plurality of staple chains can be introduced into the biological sample from the other side of the plane of the tissue section.
[0013] According to a preferred embodiment, step e), which is preferably performed before step b) and step c), comprises adjusting at least one environmental parameter of the biological sample to a first condition, under which the first plurality of staple chains are predominantly not hybridized with the folding binding site of the first nucleic acid backbone, and wherein step f), which is preferably performed after step b) and step c), comprises adjusting at least one environmental parameter of the biological sample to a second condition, under which the first plurality of staple chains are predominantly hybridized with the folding binding site of the first nucleic acid backbone. The environmental parameter may be the type of buffer salt, the concentration of buffer salt or the temperature. Predominantly in this case means that more than 50%, preferably more than 70%, more preferably more than 80% of the staple chains are not hybridized with or with the nucleic acid backbone, respectively. Thus, a change in the environmental parameter from the first condition to the second condition (e.g., by buffer exchange or temperature change) affects the binding coefficient and can trigger staple chain hybridization and folding of the compact marker.
[0014] Preferably, the first affinity agent is an oligonucleotide, an antibody or an antibody fragment. This enables the label to bind to the target analyte with high specificity. Particularly preferred are aptamers. This enables the production of particularly small and compact labels that are highly specific for the target analyte.
[0015] Preferably, the maximum spatial extent of the first affinity reagent is in the range of 1nm to 25nm, more preferably in the range of 1nm to 10nm. Alternatively, the first affinity reagent is preferably in the range of 5kDa to 200kDa, more preferably in the range of 5kDa to 70kDa, even more preferably in the range of 5kDa to 30kDa. This enables the production of a particularly small and compact marker with a high degree of specificity for the target analyte. Antibody fragments, single domain antibodies, nanobodies and aptamers are particularly suitable first affinity reagents. Alternatively or additionally, an oligonucleotide probe can be used as the first affinity reagent to label a nucleic acid target (such as genomic DNA or mRNA transcript).
[0016] Preferably, the first nucleic acid backbone has a length in the range of 100 nm to 3000 nm, preferably a length in the range of 500 nm to 2500 nm. For example, the nucleic acid backbone is produced by the M13 bacteriophage genome having a size of about 7000 nucleotides. This enables, for example, the production of a marker with a particularly bright label by being able to attach a large number of optically detectable parts.
[0017] Preferably, the first nucleic acid backbone of the first marker is folded into a shape that fits into a cuboid with a side length in the range of 10 nm to 1000 nm, preferably 50 nm to 200 nm. This enables the production of particularly compact markers.
[0018] Preferably, the biological sample is a slice (eg, a tissue slice, or a microtome slice or a vibratome slice) with a thickness ranging from 1 μm to 200 μm, preferably 5 nm to 100 μm. The method is capable of penetrating slices up to 200 μm thick.
[0019] Preferably, the first label comprises 1 to 200, preferably 50 to 100 optically detectable moieties. Each label may comprise at least one fluorophore, polyalkyne or other optically detectable moiety. This enables the generation of particularly bright labels.
[0020] Preferably, in step b), at least one second nucleic acid backbone, at least one second marker configured to be attached to the second nucleic acid backbone, and at least one second affinity reagent specific to a second target analyte in the biological sample and configured to be attached to the second nucleic acid backbone are introduced into the biological sample, and wherein in step c), a second plurality of staple chains are introduced into the biological sample, each staple chain being configured to hybridize with a paired folded binding site of the second nucleic acid backbone so as to fold the second nucleic acid backbone in the biological sample and produce a compact optically detectable second marker. This enables particularly efficient labeling of several target analytes in a biological sample. The components introduced into each of the above-mentioned steps can be carried out substantially simultaneously or subsequently in the same or different regions of the biological sample.
[0021] On the other hand, a nucleic acid backbone construct is provided, comprising: a nucleic acid backbone having paired folded binding sites configured to hybridize with complementary paired folded binding sites of a staple strand; a label attached to the nucleic acid backbone; and an affinity reagent specific for a target analyte and bound to the nucleic acid backbone. Preferably, the nucleic acid backbone construct is configured so that a method according to one of claims 1 to 13 can be performed.
[0022] In yet another aspect, a marker for labeling a biological sample is provided, the marker comprising: a nucleic acid backbone construct; and a staple strand comprising a pair of binding sites that hybridize with complementary pairs of folded binding sites of the nucleic acid backbone. BRIEF DESCRIPTION OF THE DRAWINGS
[0023] In the following, specific embodiments are described with reference to the accompanying drawings, in which:
[0024] Figure 1 is a schematic diagram of a nucleic acid construct used for a marker;
[0025] Figure 2 is based on Figure 1 A schematic diagram of a nucleic acid construct of , wherein the staple strand forms a marker; and
[0026] Figure 3 Is used according to Figure 2 Flow chart of a method for labeling a biological sample with a marker. DETAILED DESCRIPTION
[0027] Figure 1 1 is a schematic diagram of a nucleic acid construct 100. Nucleic acid construct 100 can be used to produce a marker, as explained subsequently. Nucleic acid construct 100 includes a nucleic acid backbone 102. Nucleic acid backbone 102 preferably includes 300 to 10000 nucleotides. Therefore, it is preferably 100nm to 3000nm long. For example, nucleic acid backbone 102 can include a bacteriophage-derived genomic DNA that is produced by high cell density fermentation using Escherichia coli in a stirred tank bioreactor. In particular, nucleic acid backbone 102 can be produced by M13 bacteriophage and includes approximately 7000 nucleotides.
[0028] Attached to the nucleic acid backbone 102 is a label comprising a plurality of optically detectable portions 104. For example, the optically detectable portions 104 can be fluorophores with the same optical properties (such as the same excitation and emission wavelengths). Alternatively, the optically detectable portions 104 can have a variety of different optical properties. The optically detectable portions 104 can be individually attached to the nucleic acid backbone 102 at specific binding sites 105 along the nucleic acid backbone 102.
[0029] Additionally, an affinity agent 106 is attached to the nucleic acid backbone 102. For example, the affinity agent 106 can be an antibody. Preferably, the affinity agent 106 is smaller than an antibody, for example, the affinity agent 106 can be an antibody fragment, in particular a Fab fragment, a nanobody or an aptamer. Preferably, the affinity agent 106 has a size in the range of 1 nm to 10 nm, or alternatively, has a size in the range of 5 kDa to 30 kDa.
[0030] The affinity reagent 106 is specific for a target analyte 108 in a biological sample and is therefore configured to specifically bind the nucleic acid construct 100 to the target analyte 108. The affinity reagent 106 may include an oligomer 110 that includes a binding site 112 that specifically binds to a complementary binding site 114 of the nucleic acid backbone 102. In addition, the oligomer 110 may include one or more cleavage sites 116 (e.g., restriction sites) that allow cleavage of the oligomer 110 and, therefore, removal of the nucleic acid backbone 102 having the optically detectable portion 104 from the affinity reagent 106. This is particularly useful when repeatedly staining biological samples.
[0031] Alternatively, the nucleic acid backbone 102 may be directly attached to the affinity reagent 106 without the oligomer 110 .
[0032] Figure 2 is based on Figure 1A schematic diagram of a nucleic acid construct 100 and a staple strand 200 that forms a marker 202 together with the nucleic acid construct 100. The nucleic acid backbone 102 includes pairs of folding binding sites, and the staple strands 200 are configured to be bound to the paired folding binding sites. The staple strands 200 are nucleic acid strands. Therefore, each staple strand 200 has a complementary binding site that is bound to at least one pair of folding binding sites in the paired folding binding sites of the nucleic acid backbone 102. A plurality of staple strands 200 may be present, each staple strand 200 specifically binding to a specific pair of complementary and unique folding binding sites on the nucleic acid backbone 102. The paired folding binding sites are arranged on the nucleic acid backbone 102 so that when the staple strands 200 are bound to the folding binding sites of the nucleic acid backbone 102, the nucleic acid backbone 102 is folded into a compact structure, and thus a compact optically detectable marker 202 is produced. For example, the linear nucleic acid backbone 102 can be folded into a structure such as a folded structure by pulling the linear chain of the nucleic acid backbone 102 and combining the linear chain with the staple chains 200 at regular intervals. Figure 2 The sheet shown in . Alternative geometric shapes of the compact marker 202 can be produced depending on the specific configuration and characteristics of the staple chain 200, for example, a spherical shape, a cubic shape, a tetrahedron shape, or a polyhedron shape.
[0033] Figure 3 Is used according to Figure 2 202 for marking a biological sample 300. The biological sample 300 includes at least a target analyte 108, and the method initially begins by providing the target analyte 108 to the biological sample 300. For example, the biological sample 300 may be a tissue section, in particular an expanded tissue section.
[0034] In addition, the nucleic acid backbone 102, the label including the optically detectable portion 104, and the affinity agent 106 of the nucleic acid construct 100 are introduced into the biological sample 300. Generally, several copies of the nucleic acid backbone 102, the label including the optically detectable portion 104, and the affinity agent 106 are introduced, wherein one nucleic acid backbone 102, one label including the optically detectable portion 104, and one affinity agent 106 form one nucleic acid construct 100.
[0035] The nucleic acid construct 100 may have been formed before the construct 100 is introduced into the biological sample 300. Alternatively, separate nucleic acid backbones 102, labels, and affinity reagents 106 may be introduced into the biological sample 300. The nucleic acid construct 100 is then formed within the biological sample 300. For example, a partial nucleic acid construct 100a including the nucleic acid backbone 102 and the binding label 104 may be introduced separately from the affinity reagent 106.
[0036] Within the biological sample 300 , the nucleic acid construct 100 binds to the target analyte 108 . Subsequently, the staple chain 200 can be introduced into the biological sample 300 to generate a compact marker 202 within the biological sample 300 .
[0037] Alternatively, the staple chain 200 may be introduced into the biological sample 300 first, and the nucleic acid construct 100 may be introduced subsequently. However, in another alternative, the nucleic acid construct 100 and the staple chain 200 may be introduced simultaneously in different regions of the biological sample 300. For example, in the case where the biological sample 300 is a planar tissue section, the nucleic acid construct 100 may be introduced into the biological sample 300 on one side of the plane of the tissue section, and the staple chain 200 may be introduced into the biological sample 300 on the opposite side of the plane of the tissue section.
[0038] The nucleic acid construct 100 and the staple chain 200 generally penetrate the biological sample 300 by diffusion. In addition, the individual components (particularly the nucleic acid construct 100 and the staple chain 200) generally penetrate the biological sample 300 at a faster rate than the compact marker 202. This is because: compared with the linear shape of the nucleic acid construct 100, the compact marker 202 is bulky and lacks flexibility, and when there is no staple chain 200 combined with the nucleic acid construct 100, the degree of freedom of the nucleic acid backbone 102 of the nucleic acid construct 100 is high. In order to mainly produce compact markers in the biological sample 300, it is preferred that the staple chain 200 and the nucleic acid construct 100 are introduced into the biological sample 300 separately. Once the staple chain 200 and the nucleic acid construct 100 are diffused into the biological sample 300 and are located in the same area in the sample 300, the compact marker 202 is formed. The compact marker 202 is beneficial because it reduces the area over which the marker (particularly the optically detectable portion 104) is distributed and thereby provides a marker that provides a particularly bright spot at or below the diffraction limit of an optical imaging system (e.g., an optical microscope) used to image the labeled biological sample 300.
[0039] Therefore, the nucleic acid construct 100 and the staple chain 200 are preferably introduced separately (temporally (successively) and / or spatially (in different regions of the biological sample 300)) into the biological sample 300, as described above.
[0040] In addition to diffusion, the nucleic acid construct 100 and / or the staple chain 200 can also be actively introduced into the sample 300 by means of electrophoresis caused by applying an electric field to the sample 300. This electric field can be changed or modulated, for example, in terms of the magnitude of the electric field and / or the directional distribution of the vector field of the electric field, which can support the diffusion of the nucleic acid construct 100 and / or the staple chain 200 in the sample 300.
[0041] In addition, the environmental parameters of the biological sample 300 can be adjusted to inhibit or promote the hybridization of the staple strand 200 with the nucleic acid backbone 102 and the production of the compact marker 202. For example, before the nucleic acid construct 100 and the staple strand 200 are introduced into the biological sample 300, the salt and / or concentration of the buffer in which the biological sample 300 is located can be selected to inhibit the binding of the staple strand 200 with the nucleic acid backbone 102. After the nucleic acid construct 100 and the staple strand 200 are introduced into the biological sample 300, the salt and / or concentration of the buffer in which the biological sample 300 is located can be changed to promote the binding of the staple strand 200 with the nucleic acid backbone 102. Alternatively or additionally, the temperature in which the sample 300 is located can be adjusted to inhibit or promote the binding of the staple strand 200 with the nucleic acid backbone 102.
[0042] Additional markers may be simultaneously produced through the above steps for producing marker 202 within biological sample 300. For example, similar to the above steps, a second nucleic acid backbone, a second label configured to bind to the second nucleic acid backbone, and a second affinity agent configured to bind to the second nucleic acid backbone may be introduced into biological sample 300. The second marker may be produced by introducing a second staple strand, which is configured to bind to the paired folded binding sites of the second nucleic acid backbone to produce the second marker.
[0043] In all drawings, the same or similarly acting elements are indicated by the same reference numerals. As used herein, the term "and / or" includes any and all combinations of one or more of the associated listed items and may be abbreviated as " / ".
[0044] Although some aspects have been described in the context of an apparatus, it is clear that these aspects also represent a description of a corresponding method, wherein a block or device corresponds to a method step or a feature of a method step. Similarly, aspects described in the context of a method step also represent a description of a corresponding block or item or feature of a corresponding apparatus. Reference numerals 100: Nucleic acid construct 100a: Partial nucleic acid construct 102: Nucleic acid backbone 104: Optically detectable portion 105: Binding site for an optically detectable moiety 106: Affinity reagent 108: Target Analyte 110: Oligomer 112: Binding sites on oligomers 114: Binding site on the main chain 116: Cutting site 200: Staple Chain 202: Compact marker 300: Biological samples.
Claims
1. A method for labeling a biological sample (300), a) providing at least one first target analyte (108) to a biological sample (300); b) introducing at least one first nucleic acid backbone (102), at least one first label configured to attach to the first nucleic acid backbone (102), and at least one first affinity reagent (106) specific for the first target analyte (108) and configured to attach to the first nucleic acid backbone (102) into the biological sample (300); and c) introducing a first plurality of staple chains (200) into the biological sample (300), each staple chain (200) being configured to hybridize with a pair of folding binding sites of the first nucleic acid backbone (102) so as to fold the first nucleic acid backbone (102) in the biological sample (300) and produce a compact optically detectable first marker (202).
2. The method according to claim 1, wherein steps b) and c) are performed sequentially.
3. The method according to one of the preceding claims, wherein between step b) and step c) a step d) of waiting for a time in the range of 10 seconds to 120 minutes, preferably waiting for a time in the range of 5 minutes to 90 minutes, more preferably waiting for a time in the range of 10 minutes to 60 minutes is performed. The method according to claim 3 , wherein in step d), an electrophoretic electric field is additionally applied to the biological sample.
5. A method according to one of the preceding claims, wherein the first nucleic acid backbone (102), the first label and the first affinity reagent (106) of step b) are introduced into a first region of the biological sample (300), and the first plurality of staple chains (200) of step c) are introduced into a second region of the biological sample (300), wherein the first region and the second region are spatially separated from each other.
6. A method according to one of the preceding claims, wherein step e) preferably performed before step b) and step c) comprises adjusting at least one environmental parameter of the biological sample (300) to a first condition, under which the first plurality of staple chains (200) do not primarily hybridize to the folding binding site of the first nucleic acid backbone (102), and wherein step f) preferably performed after step b) and step c) comprises adjusting at least one environmental parameter of the biological sample to a second condition, under which the first plurality of staple chains (200) primarily hybridize to the folding binding site of the first nucleic acid backbone (102).
7. The method according to one of the preceding claims, wherein the first affinity reagent (106) is an oligonucleotide, an antibody or an antibody fragment.
8. The method according to one of the preceding claims, wherein the maximum spatial extent of the first affinity reagent (106) is in the range of 1 nm to 25 nm.
9. The method according to one of the preceding claims, wherein the first nucleic acid backbone (102) has a length in the range of 100 nm to 3000 nm, preferably in the range of 500 nm to 2500 nm.
10. The method according to one of the preceding claims, wherein the first nucleic acid backbone (102) of the first marker (202) is folded into a shape suitable for a cuboid with a side length in the range of 10 nm to 1000 nm, preferably 50 nm to 200 nm.
11. The method according to one of the preceding claims, wherein the biological sample (300) is a slice having a thickness in the range of 1 μm to 200 μm, preferably 5 nm to 100 μm.
12. The method according to one of the preceding claims, wherein the first label comprises 1 to 200, preferably 50 to 100, optically detectable parts (104).
13. A method according to one of the preceding claims, wherein in step b), at least one second nucleic acid backbone, at least one second marker configured to attach to the second nucleic acid backbone, and at least one second affinity reagent specific for a second target analyte in the biological sample and configured to attach to the second nucleic acid backbone are introduced into the biological sample, and wherein in step c), a second plurality of staple chains are introduced into the biological sample, each staple chain being configured to hybridize with a pair of folding binding sites of the second nucleic acid backbone so as to fold the second nucleic acid backbone in the biological sample and produce a compact optically detectable second marker.
14. A nucleic acid backbone construct (100), comprising: a nucleic acid backbone (102) having a pair of folded binding sites configured to hybridize with complementary pair of folded binding sites of the staple strand (200); a label, the label being attached to the nucleic acid backbone (102); as well as An affinity reagent (106) that is specific for a target analyte (108) and binds to the nucleic acid backbone (102).
15. A marker (202) for marking a biological sample (300), the marker (202) comprising: The nucleic acid backbone construct (100) according to claim 14; and A staple strand (200) comprising a pair of binding sites that hybridize with complementary pairs of folded binding sites of a nucleic acid backbone (102).
